Expression data upon treatment of human mesothelioma mouse model with nucleolin-targeted nanoparticle (PEGASEMP)

The goal of this study was to identify transcriptome alterations behind the antitumor effect of PEGASEMP, a liposomal formulation of doxorubicin targeted by the nucleolin-binding F3 peptide, and hence infer on the mechanism of action. It was used microarray technology to assess the gene expression alterations upon treatment of a human biphasic mesothelioma orthotopic mouse model (aggressive disease subtype) with PEGASEMP. Tumor masses were collected from either PEGASEMP-treated or non-treated animals for RNA extraction and hybridization on Affymetrix arrays.